Solventum Corporation $SOLV Stock Holdings Lowered by Boston Partners

Boston Partners lessened its stake in Solventum Corporation (NYSE:SOLV) by 11.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,085,487 shares of the company’s stock after selling 544,813 shares during the period. Boston Partners’ holdings in Solventum were worth $323,743,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Independent Franchise Partners LLP grew its position in Solventum by 27.2% in the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after buying an additional 2,758,174 shares in the last quarter. Norges Bank bought a new position in Solventum in the 4th quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. grew its position in Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares in the last quarter. Vanguard Group Inc. grew its position in Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after buying an additional 867,837 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares in the last quarter.

Solventum Price Performance

Solventum stock opened at $78.85 on Friday. The firm has a market capitalization of $13.66 billion, a P/E ratio of 9.66, a PEG ratio of 1.22 and a beta of 0.69. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The business has a 50-day moving average of $72.50 and a 200-day moving average of $75.26. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the firm earned $1.34 EPS. Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Wedbush assumed coverage on shares of Solventum in a research report on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective for the company. UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Thursday, May 14th. Finally, Piper Sandler reduced their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.